Human Trials

AstraZeneca’s anifrolumab meets primary endpoint in phase III SLE trial

AstraZeneca’s new medicine anifrolumab has achieved primary endpoint in the phase III Tulip 2 trial of systemic lupus erythematosus (SLE).

VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs

VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).

BeyondSpring’s Plinabulin demonstrates superior quality of life in phase 2/3 study in Neutropenia

BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention of Neutropenia.”

Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial

ViiV Healthcare said that the injectable two-drug regimen of cabotegravir and rilpivirine succeeded in the ATLAS-2M phase 3 trial in adult patients with HIV-1 by meeting the primary endpoint.

AstraZeneca’s Farxiga meets primary endpoint in phase III heart failure study

AstraZeneca’s heart failure treatment Farxiga (dapagliflozin) has achieved the primary composite endpoint in the phase III DAPA-HF study.

Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic asthma

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma.

Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial

AstraZeneca and MSD said that Lynparza (olaparib) in combination with standard-of-care (SoC) bevacizumab succeeded in a phase 3 trial in advanced ovarian cancer by meeting the primary endpoint.

Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial

Eli Lilly and Company (NYSE: LLY) announced today Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study

AstraZeneca’s Tagrisso (osimertinib) has significantly improved overall survival (OS) in the patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer in the phase III Flaura trial.